ELYM Stock Price, Eliem Therapeutics, Inc. Quote, Chart

Market Summary

USD9.74-0.46

Delayedas of 08 May 2024, 01:55 pm

-4.51%

ELYM Stock Price

View Fullscreen

ELYM RSI Chart

ELYM Valuation

Market Cap

282.8M

Price/Earnings (Trailing)

-8.05

Price/Sales (Trailing)

61.21

Price/Free Cashflow

-13.73

ELYM Price/Sales (Trailing)

ELYM Profitability

Return on Equity

-32.64%

Return on Assets

-31.79%

Free Cashflow Yield

-7.28%

ELYM Fundamentals

ELYM Revenue

Revenue (TTM)

4.6M

Rev. Growth (Yr)

80.71%

Rev. Growth (Qtr)

6.98%

ELYM Earnings

Earnings (TTM)

-35.1M

Earnings Growth (Yr)

53.09%

Earnings Growth (Qtr)

8.24%

Breaking Down ELYM Revenue

52 Week Range

10.86

(Low)(High)

Last 7 days

44.6%

Last 30 days

294.2%

Last 90 days

279.6%

Trailing 12 Months

204.2%

How does ELYM drawdown profile look like?

ELYM Financial Health

Current Ratio

38.92

ELYM Investor Care

Shares Dilution (1Y)

2.78%

Diluted EPS (TTM)

-1.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	2.5M	3.5M	4.6M
2022	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Eliem Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	morisset valerie	acquired	3.5694	0.0002	17,847	evp, r&d and cso
Sep 20, 2023	morisset valerie	acquired	13.9214	0.000671623	20,728	evp, r&d and cso
Mar 10, 2023	morisset valerie	acquired	522	0.0016519	316,410	evp, r&d and cso
Aug 12, 2021	ra capital management, l.p.	bought	40,000,000	12.5	3,200,000	-
Aug 12, 2021	ra capital management, l.p.	acquired	-	-	6,867,520	-
Aug 12, 2021	ai eti llc	bought	10,000,000	12.5	800,000	-
Aug 12, 2021	ai eti llc	acquired	-	-	4,209,400	-

Which funds bought or sold ELYM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	Chicago Partners Investment Group LLC	reduced	-0.46	9,153	45,390	-%
Apr 24, 2024	BML Capital Management, LLC	added	0.63	124,853	6,010,850	3.96%
Mar 11, 2024	VANGUARD GROUP INC	added	0.21	23,483	838,312	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-35.71	-	-	-%
Feb 14, 2024	Driehaus Capital Management LLC	unchanged	-	56,818	2,191,540	0.03%
Feb 14, 2024	STATE STREET CORP	unchanged	-	868	58,156	-%
Feb 14, 2024	Tudor Investment Corp Et Al	reduced	-0.72	1,501	79,623	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-99.78	-3,648	8.00	-%
Feb 14, 2024	SILVERARC CAPITAL MANAGEMENT, LLC	sold off	-100	-318,519	-	-%

Are Funds Buying or Selling ELYM?

Are funds buying ELYM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ELYM

No. of Funds

Unveiling Eliem Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 12, 2024	ra capital management, l.p.	47.5%	13,189,736	SC 13D/A
Mar 18, 2024	ra capital management, l.p.	47.5%	13,179,181	SC 13D/A
Feb 07, 2024	bml investment partners, l.p.	7.9%	2,180,000	SC 13G/A
Nov 17, 2023	ra capital management, l.p.	47.7%	13,176,403	SC 13D/A
Nov 13, 2023	ai eti llc	18.5%	5,009,400	SC 13D/A
Apr 10, 2023	ra capital management, l.p.	48.8%	13,163,071	SC 13D/A
Mar 08, 2023	intermediate capital group plc	7.5%	2,002,563	SC 13G/A
Feb 14, 2023	samlyn capital, llc	0%	0	SC 13G/A
Feb 08, 2023	bml investment partners, l.p.	6.9%	1,825,134	SC 13G/A
Sep 22, 2022	icg life sciences scsp	7.5%	2,002,563	SC 13G

Recent SEC filings of Eliem Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 07, 2024	SC 13G	Major Ownership Report
Apr 29, 2024	10-K/A	Annual Report
Apr 12, 2024	SC 13D/A	13D - Major Acquisition
Apr 11, 2024	DEFA14A	DEFA14A
Apr 11, 2024	8-K	Current Report
Apr 08, 2024	4	Insider Trading
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	10-K	Annual Report
Mar 20, 2024	4	Insider Trading
Mar 19, 2024	8-K	Current Report

Peers (Alternatives to Eliem Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Eliem Therapeutics, Inc. News

Latest updates

Eliem Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)						(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2
Revenue	7.0%	1,349	1,261	1,110	747	383	147
Operating Expenses	2.4%	5,122	5,001	6,714	9,554	8,748	13,701
S&GA Expenses	-6.1%	1,995	2,125	3,026	4,627	4,490	4,932
R&D Expenses	8.7%	3,127	2,876	3,688	4,927	4,258	8,769
Income Taxes	-	-	-	-	-	-	-
Net Income	8.2%	-3,641	-3,968	-5,220	-7,762	-9,682	-14,596
Net Income Margin	31.5%	-7.60*	-11.09*	-18.30*	-32.90*	-	-
Free Cashflow	-127.1%	-947	3,490	-7,965	-8,449	-4,175	-13,966

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-2.0%	110	113	116	122	135	141	150	162	173	182	108	25.00
Current Assets	-1.9%	110	112	114	120	134	133	133	133	148	159	105	22.00
Cash Equivalents	62.3%	93.00	57.00	25.00	34.00	44.00	36.00	33.00	32.00	47.00	63.00	99.00	20.00
Liabilities	-4.1%	3.00	3.00	4.00	5.00	6.00	6.00	8.00	7.00	6.00	6.00	6.00	3.00
Current Liabilities	-2.3%	3.00	3.00	4.00	5.00	6.00	6.00	8.00	7.00	6.00	6.00	6.00	3.00
Shareholder's Equity	-2.0%	108	110	113	117	129	134	142	155	167	177	-	-
Retained Earnings	-2.4%	-155	-152	-148	-143	-120	-113	-103	-88.82	-75.62	-65.07	-55.46	-28.14
Additional Paid-In Capital	0.6%	264	262	261	260	250	248	246	244	243	242	5.00	3.00
Shares Outstanding	0.8%	28.00	27.00	27.00	27.00	27.00	26.00	26.00	26.00	27.00	8.00	3.00	3.00
Float	-	-	-	13.00	-	-	-	14.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-127.1%	-947	3,490	-7,965	-15,177	-8,449	-4,175	-13,966	-10,779	-7,884	-12,967	-8,481	-6,740	-	-	-
Share Based Compensation	83.2%	1,202	656	777	10,171	1,895	1,783	1,772	1,541	1,154	1,236	1,050	297	-	-	-
Cashflow From Investing	31.1%	36,748	28,037	-1,601	5,797	14,278	8,509	15,688	-4,035	-8,051	-106,919	-	-	-	-	-
Cashflow From Financing	-45.5%	288	528	24.00	1.00	-	-	-	-	38.00	83,144	59,967	34,083	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ELYM Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 15,411	$ 26,214
General and administrative	24,864	18,921
Total operating expenses	40,275	45,135
Loss from operations	(40,275)	(45,135)
Other income (expense):
Foreign currency gain (loss)	536	(1,484)
Interest Income, Net	4,620	1,375
Total other income (expense)	5,156	(109)
Net loss	$ (35,119)	$ (45,244)
Net loss per share attributable to common stockholders, diluted	$ (1.3)	$ (1.72)
Net loss per share attributable to common stockholders, basic	$ (1.3)	$ (1.72)
Weighted-average shares used in computing net loss per share attributable to common stockholders diluted	26,987,122	26,311,554
Weighted-average shares used in computing net loss per share attributable to common stockholders basic	26,987,122	26,311,554
Comprehensive loss:
Net loss	$ (35,119)	$ (45,244)
Other comprehensive loss:
Unrealized gain (loss) on investments, net of tax of $0	356	(235)
Comprehensive loss	$ (34,763)	$ (45,479)

ELYM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	$ 93,112	$ 43,585
Short-term marketable securities	13,686	79,981
Prepaid expenses and other current assets	3,457	10,827
Total current assets	110,255	134,393
Operating lease right-of-use assets	199	471
Other long term assets	15	128
Total assets	110,469	134,992
Current liabilities:
Accounts payable	66	750
Accrued expenses and other current liabilities	2,433	5,047
Operating lease liabilities	334	300
Total current liabilities	2,833	6,097
Other long-term liabilities	22	0
Operating lease liabilities, net of current portion	15	180
Total liabilities	2,870	6,277
Commitments and contingencies (Note 5)
Stockholders' equity
Common stock, $0.0001 par value per share, 250,000,000 shares authorized; 27,697,076 and 26,567,681 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	3	3
Additional paid-in capital	263,577	249,930
Accumulated other comprehensive loss	(2)	(358)
Accumulated deficit	(155,979)	(120,860)
Total stockholders’ deficit	107,599	128,715
Total liabilities and stockholders' equity	$ 110,469	$ 134,992

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

WEBSITE	https://eliemtx.com
INDUSTRY	Biotechnology
EMPLOYEES	30

Eliem Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Eliem Therapeutics, Inc.? What does ELYM stand for in stocks?

ELYM is the stock ticker symbol of Eliem Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eliem Therapeutics, Inc. (ELYM)?

As of Tue May 07 2024, market cap of Eliem Therapeutics, Inc. is 282.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELYM stock?

You can check ELYM's fair value in chart for subscribers.

What is the fair value of ELYM stock?

You can check ELYM's fair value in chart for subscribers. The fair value of Eliem Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eliem Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ELYM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eliem Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ELYM is over valued or under valued. Whether Eliem Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Eliem Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELYM.

What is Eliem Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, ELYM's PE ratio (Price to Earnings) is -8.05 and Price to Sales (PS) ratio is 61.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELYM PE ratio will change depending on the future growth rate expectations of investors.